Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

Karl Bodin, Stephan Ellmerich, Melvyn C. Kahan, Glenys A. Tennent, Andrzej Loesch, Janet A. Gilbertson, Winston L. Hutchinson, Palma P. Mangione, J. Ruth Gallimore, David J. Millar, Shane Minogue, Amar P. Dhillon, Graham W. Taylor, Arthur R. Bradwell, Aviva Petrie, Julian D. Gillmore, Vittorio Bellotti, Marina Botto, Philip N. Hawkins and Mark B. Pepys ()
Additional contact information
Karl Bodin: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Stephan Ellmerich: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Melvyn C. Kahan: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Glenys A. Tennent: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Andrzej Loesch: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Janet A. Gilbertson: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Winston L. Hutchinson: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Palma P. Mangione: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
J. Ruth Gallimore: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
David J. Millar: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Shane Minogue: Centre for Molecular Cell Biology, University College London, Royal Free Campus
Amar P. Dhillon: University College London, Royal Free Campus
Graham W. Taylor: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Arthur R. Bradwell: The Medical School, University of Birmingham
Aviva Petrie: Biostatistics Unit, UCL Eastman Dental Institute
Julian D. Gillmore: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Vittorio Bellotti: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Marina Botto: Rheumatology Section, Faculty of Medicine, Imperial College London, Hammersmith Campus
Philip N. Hawkins: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus
Mark B. Pepys: Centre for Amyloidosis and Acute Phase Proteins, University College London, Royal Free Campus

Nature, 2010, vol. 468, issue 7320, 93-97

Abstract: Dual attack on amyloidosis Systemic amyloidosis is a serious disease caused by accumulation of amyloid fibrils in the viscera and connective tissues. Serum amyloid P (SAP) is a normal plasma protein that concentrates within the amyloid deposits. Working in a mouse model of the disease, Mark Pepys and colleagues find that a combination of a drug that depletes circulating SAP and an antibody that targets residual SAP within the deposits results in clearance of amyloid deposits. A humanized version of the anti-SAP antibody has been developed with a view to clinical evaluation of this dual approach.

Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature09494 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:468:y:2010:i:7320:d:10.1038_nature09494

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature09494

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().